Item 8.01. Other Events.

Convertible Notes Repurchase

On May 31, 2022, Neurocrine Biosciences, Inc. (the "Company") entered into separate, privately negotiated transactions (the "Agreements") with certain holders of its existing 2.25% Convertible Senior Notes due 2024 (the "2024 Notes") to repurchase approximately $31.4 million aggregate principal amount of the 2024 Notes for an aggregate repurchase price of approximately $41.5 million, including accrued and unpaid interest. The 2024 Notes repurchases are expected to close on June 2, 2022, subject to customary closing conditions. Such repurchases of the 2024 Notes could affect the market price of the Company's common stock and are in addition to the repurchases of the 2024 Notes that the Company previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission on May 25, 2022.

Forward-Looking Statements

In addition to historical facts, this Current Report on Form 8-K contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the amount of 2024 Notes to be repurchased, the timing of completion of the repurchases, and the impact of the repurchases on the market price of the Company's common stock. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: changes in the price of the Company's common stock; changes in the convertible note and other capital markets; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2022. The Company disclaims any obligation to update the statements contained in this Current Report on Form 8-K after the date hereof.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses